Serum markers in rheumatoid arthritis: A longitudinal study of patients undergoing infliximab treatment

International Journal of Rheumatology

Volumn 2015, Issue , 2015, Pages

  Selaas, Oddgeir ^a   Nordal, Hilde H ^a,b   Halse, Anne Kristine ^b   Brun, Johan G ^b   Jonsson, Roland ^a   Brokstad, Karl A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LYMPHOTOXIN; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IMMUNOASSAY; JOINT INJURY; JOINT RADIOGRAPHY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NORWAY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION;

EID: 84953896334     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2015/276815     Document Type: Article

References (31)

1. P. S. Gulko and R. J. Winchester, "Rheumatoid arthitis, " in Samters Immunologic Diseases, K. F. Austen, M. M. Frank, J. P. Atkinson, and H. Cantor, Eds. , chapter 37, pp. 427-463, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001.
2. A. L. M. A. Jansen, I. E. van der Horst-Bruinsma, D. van Schaardenburg, R. J. van de Stadt, M. H. M. T. de Koning, and B. A. C. Dijkmans, "Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis, " Journal of Rheumatology, vol. 29, no. 10, pp. 2074-2076, 2002.
3. A. Kastbom, G. Strandberg, A. Lindroos, and T. Skogh, "Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project), " Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1085-1089, 2004.
4. I. K. Gao, A. Haas-Wohrle, K. G. Mueller, H.-M. Lorenz, and C. Fiehn, "Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist?" Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1516-1517, 2005.
5. M. L. L. Prevoo, M. A. vanT Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van De Putte, and P. L. C. M. van Riel, "Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, " Arthritis & Rheumatism, vol. 38, no. 1, pp. 44-48, 1995.
6. J. S. Smolen, F. C. Breedveld, M. H. Schiff et al. , "A simplified disease activity index for rheumatoid arthritis for use in clinical practice, " Rheumatology, vol. 42, no. 2, pp. 244-257, 2003.
7. Y. Yazici and I. Simsek, "Tools for monitoring remission in rheumatoid arthritis: any will do, lets just pick one and start measuring, " Arthritis Research and Therapy, vol. 15, no. 1, article 104, 2013.
8. D. Aletaha, T. Neogi, A. J. Silman et al. , "2010 Rheumatoid arthritis classification criteria: an AmericanCollege ofRheumatology/ European League Against Rheumatism collaborative initiative, " Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569-2581, 2010.
9. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al. , "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, " Arthritis and Rheumatism, vol. 31, no. 3, pp. 315-324, 1988.
10. A. G. Kvalvik, L. Lefsaker, S. Dyvik, and J. G. Brun, "Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: three-year effectiveness in patients with rheumatoid arthritis, " Joint Bone Spine, vol. 74, no. 6, pp. 606-611, 2007.
11. D. M. F. M. van der Heijde, "Radiographic imaging: the gold standard for assessment of disease progression in rheumatoid arthritis, " Rheumatology, vol. 39, supplement 1, pp. 9-16, 2000.
12. R. Maini, E. W. St Clair, F. Breedveld et al. , "Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, "TheLancet, vol. 354, no. 9194, pp. 1932-1939, 1999.
13. H. T. Ozer and Z. Ozbalkan, "Clinical efficacy of TNF-α inhibitors: an update, " International Journal of Clinical Rheumatology, vol. 5, no. 1, pp. 101-115, 2010.
14. R. N. Maini, F. C. Breedveld, J. R. Kalden et al. , "Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 41, no. 9, pp. 1552-1563, 1998.
15. M. Feldmann and R. N. Maini, "Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?" The Journal of Immunology, vol. 185, no. 2, pp. 791-794, 2010.
16. J. G. Bode, U. Albrecht, D. Haussinger, P. C. Heinrich, and F. Schaper, "Hepatic acute phase proteins-regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-KB-dependent signaling, " European Journal of Cell Biology, vol. 91, no. 6-7, pp. 496-505, 2012.
17. K. Shimamoto, T. Ito, Y. Ozaki et al. , "Seruminterleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis, " Journal of Rheumatology, vol. 40, no. 7, pp. 1074-1081, 2013.
18. M. Ozaki, Y. Kawabe, H. Nakamura et al. , "Elevated serum cytokine levels in a rheumatoid arthritis patient with large granular lymphocyte syndrome, " Rheumatology, vol. 40, no. 5, pp. 592-593, 2001.
19. G. Kleiner, A. Marcuzzi, V. Zanin, L. Monasta, and G. Zauli, "Cytokine levels in the serum of healthy subjects, " Mediators of Inflammation, vol. 2013, Article ID 434010, 6 pages, 2013.
20. A. Page-McCaw, A. J. Ewald, and Z. Werb, "Matrix metalloproteinases and the regulation of tissue remodelling, " Nature Reviews Molecular Cell Biology, vol. 8, no. 3, pp. 221-233, 2007.
21. R. Carrasco and A. Barton, "Biomarkers of outcome in rheumatoid arthritis, " Rheumatology Reports, vol. 2, no. 1, pp. 26-38, 2010.
22. A. Ban, M. Inaba, Y. Furumitsu et al. , "Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab, " Biomedicine and Pharmacotherapy, vol. 64, no. 2, pp. 107-112, 2010.
23. J. Huang, B. Xie, Q. Li et al. , "Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis, " European Journal of Pharmacology, vol. 698, no. 1-3, pp. 429-434, 2013.
24. S.-A. Yoo, S.-K. Kwok, and W.-U. Kim, "Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention, " Mediators of Inflammation, vol. 2008, Article ID129873, 6pages, 2008.
25. Z. Szekanecz and A. E. Koch, "VEGF as an activity marker in rheumatoid arthritis, " International Journal of Clinical Rheumatology, vol. 69, pp. 1172-1178, 2010.
26. S. Konisti, S. Kiriakidis, and E. M. Paleolog, "Hypoxia-a key regulator of angiogenesis and inflammation in rheumatoid arthritis, " Nature Reviews Rheumatology, vol. 8, no. 3, pp. 153-162, 2012.
27. G. Murdaca, F. Spano, M. Miglino, and F. Puppo, "Effects of TNF-α inhibitors upon the mechanisms of action of VEGF, " Immunotherapy, vol. 5, no. 2, pp. 113-115, 2013.
28. S. Ballara, P. C. Taylor, P. Reusch et al. , "Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis, " Arthritis and Rheumatism, vol. 44, no. 9, pp. 2055-2064, 2001.
29. L. Ozgonenel, E. Cetin, S. Tutun, P. Tonbaklar, H. Aral, and G. Guvenen, "The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis, " Clinical Rheumatology, vol. 29, no. 5, pp. 473-477, 2010.
30. H. R. Kim, K. W. Kim, B. M. Kim, M. L. Cho, and S. H. Lee, "The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis, " PLoS ONE, vol. 10, no. 4, Article ID e0124909, 2015.
31. S. Kelly, M. Bombardieri, F. Humby et al. , "Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early rheumatoid arthritis: an observational study, "Arthritis Research&Therapy, vol. 17, article 18, 2015.